Firms to co-develop heart-failure drug in potential $430M deal

05/10/2013 | American City Business Journals

Trevena and Forest Laboratories entered into a licensing-option deal involving TRV027, Trevena's drug candidate for acute heart failure. Forest agreed to make a $30 million equity stake in Trevena in exchange for an option to license TRV027. If Forest exercises its option, Trevena will be entitled to as much as $430 million in milestone fees plus sales royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN